Literature DB >> 9700481

A case of Gitelman's syndrome with chondrocalcinosis.

N Hisakawa1, N Yasuoka, H Itoh, T Takao, C Jinnouchi, K Nishiya, K Hashimoto.   

Abstract

A 45-year-old Japanese woman, treated for Bartter's syndrome for 14 years, presented with complaints of numbness in her extremities and polyarthralgia. She was diagnosed to have Gitelman's syndrome with chondrocalcinosis, which were effectively treated with spironolactone and magnesium supplementation. Gitelman's syndrome is a primary renal tubular disorder characterized by hypomagnesemia and hypocalciuria with normal calcemia. The persistent hypomagnesemia is one of the causes of chondrocalcinosis, and many cases of Bartter's syndrome with hypomagnesemia are associated with chondrocalcinosis attributed to a tubular magnesium defect. We summarize the reported cases with Bartter's syndrome and chondrocalcinosis, referring to the possibility of Gitelman's syndrome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9700481     DOI: 10.1507/endocrj.45.261

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  4 in total

Review 1.  Clinical trials review: crystal deposition diseases.

Authors:  R A Terkeltaub
Journal:  Curr Rheumatol Rep       Date:  1999-12       Impact factor: 4.592

2.  Novel NCC mutants and functional analysis in a new cohort of patients with Gitelman syndrome.

Authors:  Bob Glaudemans; Helger G Yntema; Pedro San-Cristobal; Jeroen Schoots; Rolph Pfundt; Erik-J Kamsteeg; René J Bindels; Nine V A M Knoers; Joost G Hoenderop; Lies H Hoefsloot
Journal:  Eur J Hum Genet       Date:  2011-10-19       Impact factor: 4.246

Review 3.  Magnesium disorders can cause calcium pyrophosphate deposition disease: A case report and literature review.

Authors:  Akanksha Joshi; Chokkalingam Siva
Journal:  Eur J Rheumatol       Date:  2017-08-29

4.  Gitelman's syndrome (familial hypokalemia-hypomagnesemia).

Authors:  M Gjata; M Tase; A Gjata; Zh Gjergji
Journal:  Hippokratia       Date:  2007-07       Impact factor: 0.471

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.